secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001564590-22-010864
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi: Phase 2 CANAL interim p<0.0001 (52% cough reduction); PRISM enrollment done
--------------------------------------------------------------------------------

- Phase 2 CANAL interim analysis: 52% placebo-adjusted reduction in daytime cough events (p<0.0001); enrollment ended early; full data Q3 2022.
- Phase 2b/3 PRISM trial (pruritus in prurigo nodularis) completed enrollment Jan 31, 2022; top-line data expected Q2 2022.
- Q4 2021 net loss $8.5M vs $9.5M in Q4 2020; full-year net loss $33.9M vs $32.8M in 2020.
- Cash and equivalents of $36.8M as of Dec 31, 2021.
- KOL webinar on IPF chronic cough set for March 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022010864/0001564590-22-010864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022010864/trvi-8k_20220317.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-010864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer